NeuroPace (NASDAQ:NPCE) Stock Price Down 4.3% – Time to Sell?

NeuroPace, Inc. (NASDAQ:NPCE) was down 4.3% during mid-day trading on Friday . The stock traded as low as $11.78 and last traded at $11.85. Approximately 168,073 shares were traded during trading, an increase of 30% from the average daily volume of 128,856 shares. The stock had previously closed at $12.38.

Analyst Upgrades and Downgrades

Several equities research analysts have weighed in on NPCE shares. Cantor Fitzgerald raised their price objective on shares of NeuroPace from $19.00 to $20.00 and gave the company an “overweight” rating in a research report on Wednesday, March 5th. UBS Group began coverage on shares of NeuroPace in a research note on Tuesday, January 21st. They set a “buy” rating and a $17.00 price target on the stock. Wells Fargo & Company boosted their price objective on shares of NeuroPace from $13.00 to $17.00 and gave the stock an “overweight” rating in a research report on Thursday, January 30th. Finally, JPMorgan Chase & Co. increased their price objective on NeuroPace from $9.00 to $14.00 and gave the company an “overweight” rating in a research report on Tuesday, December 17th. One equities research analyst has rated the stock with a hold rating and four have issued a buy rating to the company’s stock. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus target price of $15.20.

NeuroPace Trading Down 4.3 %

The company has a market capitalization of $385.84 million, a price-to-earnings ratio of -11.85 and a beta of 2.06. The company has a debt-to-equity ratio of 6.03, a quick ratio of 4.77 and a current ratio of 5.59. The business’s 50-day simple moving average is $12.63 and its 200-day simple moving average is $10.23.

NeuroPace (NASDAQ:NPCE) last announced its quarterly earnings data on Tuesday, March 4th. The company reported ($0.18) earnings per share for the quarter, beating the consensus estimate of ($0.25) by $0.07. NeuroPace had a negative net margin of 36.74% and a negative return on equity of 205.41%. The business had revenue of $21.47 million for the quarter, compared to analyst estimates of $21.14 million. On average, research analysts expect that NeuroPace, Inc. will post -1 earnings per share for the current fiscal year.

Insider Activity

In other news, insider Martha Morrell sold 78,334 shares of the business’s stock in a transaction dated Friday, February 21st. The stock was sold at an average price of $13.72, for a total transaction of $1,074,742.48. Following the completion of the transaction, the insider now directly owns 81,993 shares in the company, valued at approximately $1,124,943.96. The trade was a 48.86 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, major shareholder Ltd. Kck sold 5,270,845 shares of the stock in a transaction that occurred on Thursday, February 20th. The shares were sold at an average price of $9.40, for a total transaction of $49,545,943.00. The disclosure for this sale can be found here. Insiders have sold a total of 5,352,479 shares of company stock valued at $50,670,217 in the last 90 days. 22.20% of the stock is owned by company insiders.

Hedge Funds Weigh In On NeuroPace

Hedge funds and other institutional investors have recently made changes to their positions in the company. KCK LTD. bought a new stake in shares of NeuroPace in the 4th quarter valued at $58,981,000. Geode Capital Management LLC grew its stake in NeuroPace by 1.8% in the fourth quarter. Geode Capital Management LLC now owns 322,973 shares of the company’s stock valued at $3,615,000 after acquiring an additional 5,781 shares during the period. Northern Trust Corp increased its holdings in shares of NeuroPace by 15.7% in the fourth quarter. Northern Trust Corp now owns 184,847 shares of the company’s stock worth $2,068,000 after acquiring an additional 25,035 shares in the last quarter. State Street Corp raised its position in shares of NeuroPace by 9.1% during the third quarter. State Street Corp now owns 155,490 shares of the company’s stock worth $1,084,000 after purchasing an additional 12,912 shares during the period. Finally, Jane Street Group LLC bought a new position in shares of NeuroPace during the 4th quarter valued at about $1,120,000. 78.83% of the stock is owned by institutional investors.

NeuroPace Company Profile

NeuroPace, Inc operates as a medical device company in the United States. The company develops RNS system, a brain-responsive neuromodulation system that delivers personalized, real-time treatment at the seizure source for treating medically refractory focal epilepsy. It also records continuous brain activity data and enables clinicians to monitor patients in person and remotely.